Company Instil Bio, Inc.

Equities

TIL

US45783C2008

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:30:00 2024-04-29 EDT			5-day change	1st Jan Change
10.48 ^USD	-1.18%		-2.19%	+37.47%

04-26	Instil Bio, Inc. Announces Board Changes	CI
04-15	North American Morning Briefing : Stock Futures -2-	DJ

Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. Its first such program is an engineered tumor infiltrating lymphocyte (TIL), cell therapy for the treatment of cancer. It is engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR), platform. The Company's lead CoStAR-TIL product candidate, ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (Fra), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer. CAR-T and TCR-T therapies are cell products composed of T cells that have been genetically engineered to recognize a specific cancer-related antigen on the surface of tumor cells.

Number of employees: 49

Managers	Title	Age	Since
Bronson Crouch CEO	Chief Executive Officer	51	18-10-31
Sandeep Laumas DFI	Director of Finance/CFO	56	20-05-31
Mark Dudley CTO	Chief Tech/Sci/R&D Officer	-	21-09-30
Robert Hawkins CTO	Chief Tech/Sci/R&D Officer	69	22-11-10
John Moore PRN	Corporate Officer/Principal	59	20-06-30

Members of the board	Title	Age	Since
Neil Gibson BRD	Director/Board Member	67	20-05-31
Richard McGaughy BRD	Director/Board Member	52	20-05-31
Gwendolyn Binder-Scholl BRD	Director/Board Member	49	20-06-30
Bronson Crouch CEO	Chief Executive Officer	51	18-10-31
George Matcham BRD	Director/Board Member	72	18-08-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	6,503,913	6,058,919 ( 93.16 %)	0	93.16 %

Name	Equities	%	Valuation
Curative Ventures Management LLC 29.20 %	1,899,004	29.20 %	21 M $
Vivo Capital LLC 9.599 %	624,338	9.599 %	7 M $
CPMG, Inc. 6.318 %	410,923	6.318 %	4 M $
BML Capital Management LLC 5.362 %	348,735	5.362 %	4 M $
BML Capital Management LLC 5.323 %	346,190	5.323 %	4 M $
Cable Car Capital LLC 3.968 %	258,097	3.968 %	3 M $
Vanguard Global Advisers LLC 2.000 %	130,102	2.000 %	1 M $
Nantahala Capital Management LLC 1.957 %	127,292	1.957 %	1 M $
Renaissance Technologies LLC 1.747 %	113,614	1.747 %	1 M $
Marshall Wace LLP 0.9321 %	60,626	0.9321 %	654 761 $

Instil Bio, Inc.

3963 Maple Avenue Suite 350

75225, Dallas

http://www.instilbio.com

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

10.48 USD

Average target price

27.67 USD

Spread / Average Target

+164.12%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
INSTIL BIO, INC.	+37.47%	68.13M
IQVIA HOLDINGS INC.	+1.77%	42.86B
LONZA GROUP AG	+47.70%	41.36B
MODERNA, INC.	+12.24%	42.74B
CELLTRION, INC.	-8.83%	27.68B
ICON PUBLIC LIMITED COMPANY	+7.44%	25.15B
ALNYLAM PHARMACEUTICALS, INC.	-23.01%	18.63B
MEDPACE HOLDINGS, INC.	+30.56%	12.37B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.82%	11.92B
UNITED THERAPEUTICS CORPORATION	+8.35%	11.21B

Other Biotechnology & Medical Research